Analysts Turned Bearish on These 10 Stocks on Wednesday

Page 1 of 3

Wall Street’s November opened with a sharp break for technology shares. On November 3, the Nasdaq 100 slid into a correction, falling 10.4% below its October 6 peak. Economist David Rosenberg of Rosenberg Research called a correction “probably inevitable.” Two days later, the slide turned into a rout that hit every major index.

The Worst Day for the Nasdaq in 19 Months

On November 5, the Nasdaq Composite fell 5.52% to 24,315.00, its deepest one-day drop in 19 months. The move confirmed a correction, leaving the index more than 10% below its October 6 record close. The S&P 500 lost 4.36% to 7,353.73, erasing about $3 trillion of market value, and the Dow Jones Industrial Average fell 3.44% to 51,523.06.

Chip stocks took the worst of it, with the Philadelphia Semiconductor index dropping more than 12%. Fears of tighter AI regulation after Democrats won control of Congress drove the selling. Melissa Brown, global head of investment decision research at SimCorp, said investors appeared to be recognizing that some newly elected members of Congress and governors want to slow the pace of AI development. Jed Ellerbroek, a portfolio manager at Argent Capital Management, called it “the capitulation phase for the data center capex beneficiary stocks, especially the semiconductors.”

Investors looking for names the selloff pushed down can start with our list of oversold AI stocks that Wall Street analysts see rising 50% or more.

Rate-Hike Bets Add Pressure

Interest rates gave the market a second problem. The Federal Reserve raised rates in September, and Fed officials Beth Hammack of the Cleveland Fed and Thomas Barkin of the Richmond Fed hinted that more hikes could follow. Traders were already betting on another increase in December when the selloff hit.

Hotter-than-expected inflation data then strengthened those bets. By November 16, markets were fully pricing in a December hike, according to the CME FedWatch tool. Fed Chair Kevin Warsh was scheduled to speak that day, and minutes of the central bank’s October meeting were due on November 18.

For readers who want the other end of the rating scale, our ranking of NYSE stocks with huge upside potential covers the names analysts like.

Rates were not the only pressure on technology shares. Ipek Ozkardeskaya, senior analyst at Swissquote, said investors who buy into a major AI public offering may sell their existing tech holdings to pay for it, which adds to the selling in a market that is already falling.

Analysts Turned Bearish on These 10 Stocks on Wednesday

A person with a cell phone who is looking for new stocks

Our Methodology

To compile this list, we reviewed analyst rating downgrades and price target cuts announced on Wednesday, November 18, 2026. We have ranked these stocks in ascending order of their average upside potential, as of November 18.

At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).

Analysts Turned Bearish on These 10 Stocks on Wednesday

10. New York Times (NYSE:NYT)

Average Upside Potential: 7%

Citi analyst Jason Bazinet moved The New York Times to Neutral from Buy on November 18 and cut his price target to $76 from $85. He pointed to deteriorating near-term engagement that could slow subscription growth, and said the near-term balance of risk and reward looks less attractive. He remains confident in the long term.

The company sells subscriptions to its journalism and its digital products, so subscriber growth carries most of the story. In the third quarter of 2026, which the company reported on November 4, it added about 420,000 net digital-only subscribers and ended with 13.76 million total subscribers. Digital-only average revenue per user rose 1.4% to $9.93.

Bazinet’s note names four measures of reader behavior: app downloads, active users, how often readers visit and how long they stay. He described all four as deteriorating, which means his concern rests on how readers use the product rather than on the subscriber total already reported. His change is about the pace of the next few quarters rather than the business’s long-term position. The shares trade at 22.49 times forward earnings.

9. Insulet (NASDAQ:PODD)

Average Upside Potential: 26%

Stifel analyst Jonathan Block cut Insulet to Hold from Buy on November 18 and lowered his price target to $165 from $180. His note cited weaker momentum in the United States.

Insulet makes the Omnipod, an insulin delivery system for people with diabetes. In the third quarter of 2026, revenue rose 19.2% to $842.0 million, with US Omnipod revenue up 14.7% and international Omnipod revenue up 31.7%. The company reported those results on November 4, so Stifel’s change in view came after both regions had grown at double-digit rates.

Block’s note centers on the larger of those two businesses, the American one. He also expects competition from other tubeless insulin pumps to compress the multiple investors will pay for the stock. The slower-growing segment is therefore the one carrying the most weight in his argument, and his argument rests on direction rather than current size. That left the company growing at a double-digit rate in every region it reports, with Stifel’s cut tied to one of them. Readers following the group can find more names in our list of healthcare stocks to buy.

Page 1 of 3